ATC Group: G03XC02 Bazedoxifene

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G03XC02 in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G03 Sex hormones and modulators of the genital system
3 G03X Other sex hormones and modulators of the genital system
4 G03XC Selective estrogen receptor modulators
5 G03XC02 Bazedoxifene

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 20 mg

Active ingredients in G03XC02

Active Ingredient Description
Bazedoxifene

Related product monographs

Title Information Source Document Type  
CONBRIZA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Croatia (HR)

Cyprus (CY)

Estonia (EE)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

Poland (PL)

Spain (ES)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.